<DOC>
	<DOCNO>NCT02578043</DOCNO>
	<brief_summary>The objective study evaluate therapeutic equivalence safety .</brief_summary>
	<brief_title>A Study Comparing Clindamycin Benzoyl Peroxide Gel 1.2 % /3.75 % Onexton™ Gel Treatment Acne Vulgaris</brief_title>
	<detailed_description>The objective study evaluate therapeutic equivalence safety test product Clindamycin Benzoyl Peroxide Gel 1.2 % /3.75 % reference product Onexton™ Gel ( Clindamycin Benzoyl Peroxide Gel 1.2 % /3.75 % ) treatment acne vulgaris demonstrate superiority efficacy test reference product placebo control .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>Healthy male non pregnant female age ≥ 12 ≤ 40 year clinical diagnosis acne vulgaris . Must minimum ≥ 25 noninflammatory lesion ≥ 20 inflammatory lesion ≤ 2 nodulocystic lesion baseline face . Must definite clinical diagnosis acne vulgaris severity grade 2 , 3 , 4 per Investigator 's Global Assessment . Female subject pregnant , nurse plan become pregnant study participation . A history presence Crohn 's disease , ulcerative colitis , regional enteritis , antibioticassociated colitis . A history hypersensitivity allergy clindamycin , benzoyl peroxide and/or study medication ingredient excipients .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>